triptorelin + human chorionic gonadotropin

The "Double trigger" protocol, as studied by Bedaya Hospital, is a pharmacological combination used in assisted reproductive technology (ART) to induce final oocyte maturation in patients undergoing in vitro fertilization (IVF). This specific regimen involves the co-administration of a gonadotropin-releasing hormone (GnRH) agonist, specifically triptorelin, and human chorionic gonadotropin (hCG). In the Bedaya Hospital clinical trial, triptorelin (0.2 mg) is administered 40 hours prior to ovum pick-up, followed by hCG (10,000 IU) 34 hours prior to the procedure. This dual approach is designed to mimic the natural mid-cycle surge of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). While hCG primarily provides LH-like activity to trigger maturation, the addition of a GnRH agonist induces an endogenous surge of both LH and FSH, which is hypothesized to improve oocyte yield, maturity, and quality, particularly in normoresponder patients.

Brand names

Choriomon

Other names

Double triggerGnRH agonist + hCG triggerGnRHa + hCG trigger